A recent study has shed light on the efficacy of CoQ10 phytosomes, specifically marketed as Ubiqsome by Indena, in enhancing cellular ubiquinone uptake in skeletal muscle cells. The crossover design study involved eight volunteers who were randomly assigned to receive 100 mg per day of CoQ10 for two weeks, either in phytosome form as a lecithin formulation or in CoQ10 crystalline form. The results indicated that both formulations exhibited equivalent plasma bioavailability in vivo. However, in vitro experiments demonstrated that lipoproteins enriched with the phytosome form displayed higher bioavailability than those enriched with the crystalline form in both human dermal fibroblasts and murine skeletal myoblast. This suggests that phytosome carriers may offer an advantage in delivering CoQ10 to skin and muscle tissues. Indena’s Ubiqsome is highlighted as a food-grade delivery system for CoQ10, formulated using the company’s proprietary “Multi-Talented Technology Platform.” Serena Tongiani, Chief Product Officer at Indena, emphasized that the study contributes to the existing scientific literature supporting the ingredient’s ability to enhance CoQ10 bioavailability and endothelial function. Tongiani expressed confidence in Ubiqsome CoQ10 Phytosome as a reliable and promising ingredient for traditional CoQ10 applications based on the accumulating evidence from recent years. This research adds valuable insights into the potential benefits of Ubiqsome in improving the delivery and effectiveness of CoQ10 in crucial tissues such as skin and muscles.